Abstract
The American Cancer Society estimates that in 2023 about 24,810 malignant brain and spinal cord tumors will be diagnosed in the United States and about 18,990 people will die from these tumors. Early detection of malignant brain tumors is crucial in improving survival. Currently, MRI is the standard radiological method used to identify brain tumors. However, these tests are prone for human error, inefficiencies, and often require invasive tissue diagnosis for confirmation. Advancement in machine learning algorithms has shown to improve accuracy in detection of brain tumors. In this study, a novel deep learning approach, called Inception Resnet, a type of pretrained Convolutional Neural Network(CNN), was used to identify and classify three common brain tumors. These classes were pituitary, meningioma, and glioma. Pituitary tumors are the most harmless of the three as they are noncancerous. This contrasts with both glioma and high grade meningioma tumors which are life-threatening. It should be noted, however, that high grade meningioma tumors are very rare. Along with these three classes, a separate control class with no brain tumors was also used. This dataset contained 5,952 MRI images that included 1621 glioma images, 574 meningioma images, 1751 pituitary images and 2000 images with no tumor. Based on this data, a model was created that was able to diagnose brain tumors with an accuracy of 96.7%.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data used in the study are available to the public online.